| Trial ID: | L0610 |
| Source ID: | IRCT2015042020951N2
|
| Associated Drug: |
H.pylori eradication
|
| Title: |
The study of treatment of Helicobacter Pylori in improvement of non-alcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Condition 1: Nonalcoholic fatty liver disease. Condition 2: Helicobacter pylori infection. <br>Fatty (change of) liver, not elsewhere classified <br>Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters;Fatty (change of) liv
|
| Interventions: |
Intervention 1: Case group: treatment of Helicobacter Pylori with omeprazole (20 mg bid), amoxicilin (1gr bid), and clarithromycin (500 mg bid) orally for 2 weeks. Intervention 2: Control group: will receive only symptomatic therapy, if indicated; for exa
|
| Outcome Measures: |
Aspartate aminotransferase. Timepoint: at the start and end of the study. Method of measurement: by clinical labratory.;Alanine aminotransferase. Timepoint: at the start and end of the study. Method of measurement: by clinical labratory.;Sonographic indices of fatty liver disease. Timepoint: at the start and end of the study. Method of measurement: by a trained sonologist.nan
|
| Sponsor/Collaborators: |
research department of medical college of QUMS
|
| Gender: |
All
|
| Age: |
18 years60 years
|
| Phases: |
Not applicable
|
| Enrollment: |
30
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.
|
| Start Date: |
12/05/2015
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/18489
|
